Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 215 results found since Jan 2013.
Statins in stroke prevention: present and future.
CONCLUSION: Traditionally, there has been no clear data demonstrating that adding other lipid-modifying drugs to statins results in a further decrease in stroke or other cardiovascular event, but now things have changed and future directions include combinations with ezetimibe and new treatments such as PCSK9 inhibitors. Only time will tell the real roll of these new promising non-statin lipid-modifying therapies on stroke prevention.
PMID: 27160755 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 9, 2016 Category: Drugs & Pharmacology Authors: Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA Tags: Curr Pharm Des Source Type: research
Gender and Cardiovascular Mortality in Northern and Ssouthern European Populations.
CONCLUSION: No doubt might still exist that all efforts were undertaken for both men and women, for health and prolongation of life to effectively treat common risk factors such as cigarette consumption, high blood pressure, cholesterol levels and physical inactivity by also paying attention to optimal diet.
PMID: 27138925 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 1, 2016 Category: Drugs & Pharmacology Authors: Puddu PE, Schiariti M, Torromeo C Tags: Curr Pharm Des Source Type: research
Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
PMID: 26924325 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - February 29, 2016 Category: Drugs & Pharmacology Authors: Siniscalchi A, Sanguigni S, Lochner P, De Sarro G, Malferrari G, Gallelli L Tags: Curr Vasc Pharmacol Source Type: research
Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
issued a Complete Response Letter regarding Merck's Supplemental New
Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk
of cardiovascular events (cardiovascular death, nonfatal myocardial
infarction, nonfatal stroke, hospitalization for unstable angina, or
need for revascularization) in patients with coronary heart disease.
Language:
...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Receives Complete Response Letter from the U.S. FDA for ZETIA ® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City:
KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
issued a Complete Response Letter regarding Merck ' s Supplemental New
Drug Applications for ZETIA ® and VYTORIN® for the reduction of the risk
of cardiovascular events (cardiovascular death, nonfatal myocardial
infarction, nonfatal stroke, hospitalization for unstable angina, or
need for revascularization) in patients with coronary heart disease. Language:
English ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
Conclusions
Paradoxical statin-induced reduction in HDL-C was relatively common and was associated with increased risk of MACE.
Source: Clinical Drug Investigation - December 30, 2015 Category: Drugs & Pharmacology Source Type: research
Relationship between pre-stroke cardiovascular medication use and stroke severity
Conclusion
Pre-stroke use of statins is significantly associated with lower stroke severity. No significant relationship was detected between pre-stroke use of other medication groups and stroke severity, defined by the NIHSS score.
Source: European Journal of Clinical Pharmacology - December 26, 2015 Category: Drugs & Pharmacology Source Type: research
Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes
ConclusionsIn diabetes, poor statin adherence may considerably increase the risk of IS both in primary and secondary prevention of IS. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - December 21, 2015 Category: Drugs & Pharmacology Authors: Maarit Jaana Korhonen, Päivi Ruokoniemi, Jenni Ilomäki, Atte Meretoja, Arja Helin‐Salmivaara, Risto Huupponen Tags: Original Report Source Type: research
The Role of Statin Therapy in Hemorrhagic Stroke
The 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) are the most widely utilized class of cholesterol‐lowering agents, carrying multiple indications for both primary and secondary cardiovascular risk reduction. Concern was raised by previously published post hoc analyses and observational studies that noted an increased risk of hemorrhagic stroke in patients receiving a statin. Subsequent studies have demonstrated conflicting results regarding the role of statin therapy on hemorrhagic stroke risk and patient outcomes. New evidence suggests that statins taken prior to or continued during admissi...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 19, 2015 Category: Drugs & Pharmacology Authors: Andrea Sikora Newsome, Bryan C. Casciere, J. Dedrick Jordan, Denise H. Rhoney, Kelly A. Sullivan, Kathryn A. Morbitzer, Joseph D. Moore, Emily A. Durr Tags: Review of Therapeutics Source Type: research
Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII.
PMID: 26459809 [PubMed - in process]
Source: Current Vascular Pharmacology - October 16, 2015 Category: Drugs & Pharmacology Authors: Athyros VG, Tziomalos K, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research
Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischemia
CONCLUSIONS AND IMPLICATIONSAcute atorvastatin provides global cerebral protection, but only at the higher dose of 20 mg/kg/d, related to a reduction of inflammation in both vascular and parenchymal compartments. Our results suggest that atorvastatin could also be beneficial when administered early after stroke.
Source: British Journal of Pharmacology - August 19, 2015 Category: Drugs & Pharmacology Authors: C Potey, T Ouk, O Petrault, M Petrault, V Berezowski, J Salleron, R Bordet, S Gautier Tags: RESEARCH PAPER Source Type: research
Statins for early stage chronic kidney disease: an overview of reviews.
CONCLUSION: Statins reduce the incidence of death and other relevant outcomes in patients with early stage chronic kidney disease and should be considered for such individuals who also present hyperlipidemia.
PMID: 24720455 [PubMed - in process]
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research
Anti-apoptotic serpins as therapeutics in cardiovascular diseases.
Authors: Kuiper J, Quax PH, Bot I
Abstract
Acute cardiovascular syndromes such as myocardial infarction and stroke are a major cause of death in the Western society and are generally caused by rupture of an atherosclerotic plaque. Treatment of atherosclerosis, the main underlying cause of acute cardiovascular syndromes, is still inadequate for most of the patients. Therefore, there is a need for new therapeutic strategies in addition to the existing lipid-lowering drugs such as statins. Lipid accumulation, inflammation and matrix degradation are generally considered key processes in the pathogenesis of atherosclero...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research
Increasing compliance with national quality measures for stroke through use of a standard order set.
CONCLUSION: A retrospective review of the treatment records of patients hospitalized for acute stroke showed that adherence to national guidelines was increased when providers used a standard order set.
PMID: 25991597 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - May 21, 2015 Category: Drugs & Pharmacology Authors: Elder KG, Lemon SK, Costello TJ Tags: Am J Health Syst Pharm Source Type: research
PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N -of-1 Trials
Abstract
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel class of medications that greatly lower low-density lipoprotein cholesterol (LDL-C) by upregulating LDL receptor availability. In early 2014, the US Food and Drug Administration (FDA) directed developers of PCSK9 inhibitors to monitor neurocognitive adverse effects and consider neurocognitive testing in at least a subset of participants in ongoing late-stage trials. Available trial evidence indicates that neurocognitive adverse events may occur more commonly in individuals receiving an antibody to PCSK9, but these events are unco...
Source: Drug Safety - May 20, 2015 Category: Drugs & Pharmacology Source Type: research
